Loading...

INDP INDAPTUS THERAPEUTICS INC Management Changes 8-K Filing

NDPT

NDP

INDAPTUS THERAPEUTICS INC

(INDP)

2026 8-K

Management Changes

Management Changes

Stockholder Meeting Results

Warrant Repricing Agreement

Management Changes

Board Expansion

Board Resignations

Capital Raise Agreement

Financial Press Release

Clinical Trial Update

Financial Results

Private Placement

Voluntary Delisting

Equity Offerings

Reverse Stock Split

Private Placement

Financial Statements

Financial Results

Equity Purchase Agreement

Nasdaq Compliance

Private Placement

Securities Offering

Financial Results

Clinical Supply Agreement

Financial Results

Securities Purchase Agreements

Annual Meeting and Plan Ame...

Phase I Trial Advancement

Financial Results Announcement

Research Presentation

Financial Results Announcement

Positive Trial Results

Bylaws Amendments

Financial Results Announcement

Interim Data Presentation

Interim Data Release

Financial Results Announcement

Clinical Trial Update

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Appointment of Director

External Links:

Indaptus Therapeutics, Inc. announced on January 20, 2026, that it has adjusted the salaries of its Co-CEO and Chief Science Officer to $60,000 annually and confirmed that Board member Anthony Maddaluna will remain on the Board after initially planning to resign.

AI Assistant

INDAPTUS THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.